HC Wainwright Issues Optimistic Estimate for ALNY Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Research analysts at HC Wainwright increased their Q2 2025 EPS estimates for Alnylam Pharmaceuticals in a report issued on Monday, June 2nd. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will earn ($0.57) per share for the quarter, up from their prior estimate of ($1.14). HC Wainwright currently has a "Buy" rating and a $500.00 target price on the stock. The consensus estimate for Alnylam Pharmaceuticals' current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Alnylam Pharmaceuticals' Q3 2025 earnings at ($0.64) EPS, Q4 2025 earnings at $0.50 EPS, FY2025 earnings at ($1.15) EPS, FY2026 earnings at $11.96 EPS, FY2027 earnings at $26.89 EPS and FY2028 earnings at $30.21 EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The firm had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same period in the previous year, the business earned ($0.16) EPS. The business's quarterly revenue was up 20.2% on a year-over-year basis.

Several other research analysts also recently issued reports on ALNY. Redburn Atlantic began coverage on Alnylam Pharmaceuticals in a research note on Monday, March 31st. They issued a "buy" rating and a $353.00 price objective for the company. Stifel Nicolaus raised their price target on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research note on Monday, March 31st. William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Canaccord Genuity Group raised their target price on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. Finally, JPMorgan Chase & Co. raised Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $280.00 to $328.00 in a report on Monday, March 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $319.17.

Alnylam Pharmaceuticals Trading Down 2.3%

Alnylam Pharmaceuticals stock traded down $7.17 during trading hours on Thursday, hitting $300.83. The stock had a trading volume of 954,848 shares, compared to its average volume of 930,178. The business's 50 day simple moving average is $263.27 and its 200-day simple moving average is $256.68. Alnylam Pharmaceuticals has a one year low of $147.25 and a one year high of $310.58. The stock has a market cap of $39.22 billion, a price-to-earnings ratio of -138.63 and a beta of 0.17. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 31,640 shares of the firm's stock in a transaction on Friday, May 30th. The shares were sold at an average price of $304.39, for a total value of $9,630,899.60. Following the transaction, the chief executive officer now directly owns 48,948 shares of the company's stock, valued at approximately $14,899,281.72. This trade represents a 39.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.50% of the company's stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Strs Ohio bought a new stake in Alnylam Pharmaceuticals during the 1st quarter worth approximately $7,781,000. Geneos Wealth Management Inc. boosted its position in shares of Alnylam Pharmaceuticals by 372.3% during the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company's stock valued at $60,000 after buying an additional 175 shares during the last quarter. IFM Investors Pty Ltd grew its holdings in Alnylam Pharmaceuticals by 0.6% during the first quarter. IFM Investors Pty Ltd now owns 23,850 shares of the biopharmaceutical company's stock worth $6,440,000 after buying an additional 150 shares in the last quarter. Bayforest Capital Ltd grew its holdings in Alnylam Pharmaceuticals by 14.6% during the first quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company's stock worth $83,000 after buying an additional 39 shares in the last quarter. Finally, SCS Capital Management LLC purchased a new stake in Alnylam Pharmaceuticals in the 1st quarter valued at $46,194,000. Institutional investors and hedge funds own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.